MK-1088 + pembrolizumab

MK-1088 + pembrolizumab is an **investigational combination therapy** being studied for the treatment of advanced or metastatic solid tumors. MK-1088 is an oral small molecule immunomodulator (mechanistic class undisclosed in public documents), and pembrolizumab (Keytruda) is a monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor. This combination is being tested to evaluate safety, tolerability, dose-limiting toxicities, pharmacokinetics, and anti-tumor activity in patients whose cancer has not responded to prior standard therapies. The regimen typically consists of oral MK-1088 (50–100 mg daily for days 1–21 of each 21-day cycle) and intravenous pembrolizumab (every 3 weeks, up to 35 cycles). MK-1088 is under development by Merck Sharp & Dohme (MSD), and the combination is in phase 1/2 clinical trials for patients with solid tumors.

Other names

pembrolizumabMK-1088 + pembrolizumab